Providing investors with the
tools to make informed decisions.
Providing investors with the
tools to make informed decisions.
 Tracking 1050 U.S. listed China Stocks and Counting...
 Tracking 1535 U.S. Stocks and Counting...

 China Botanic (NYSE AMEX:CBP)

At least one FIE exists in the corporate structure

Company Description

Renhuang Pharmaceuticals is an integrated developer, manufacturer and distributor of a broad line of high-quality nutraceutical, biopharmaceutical, and natural medicinal products. The Company provides three major product lines including the Acanthopanax-based natural medicinal products, biopharmaceutical products, and Traditional Chinese Medicines, currently representing roughly 50%, 20%, and 30% of total revenues, respectively. Renhuang’s key product line is an Acanthopanax-based product series, a natural medicine effective in treating depression and melancholy, and provides numerous other health benefits. By controlling an estimated 70% of China’s natural resource of Acanthopanax (also known as Siberian Ginseng), the Company possesses a unique competitive edge and, therefore, occupies a dominant market position in Acanthopanax-based medicinal and nutraceutical products.

Renhuang distributes its products through a multi-layered sales network of over 2,000 sales agents organized under 70 sales centers across 24 districts that cover over 50% of greater China. Its products are not only sold nationwide but also exported to Russia and Southeast Asia.

Web site: http://www.renhuang.com

Last updated May 4, 2009